Title: Clinical efficacy study of rosiglitazone combined with bicyclol in treatment of non-alcoholic fatty liver
Abstract: Objective To investigate the clinical efficacy of rosiglitazone combined with bicyclol in treatment of non-alcoholic fatty liver.Methods 65 patients with non-alcoholic fatty liver were randomly divided into treatment group(n=33) and control group(n=32).The control group was only treated with conventional treatment,and the treatment group was treated with rosiglitazone and bicyclol on the basis of control group.The treatment duration lasted 24 weeks for both groups.The clinical efficacy and serological indicators changes of two groups were compared after treatment.Results The total effective rate of treatment group(88.4%) was significantly better than that of control group(74.4%)(P0.05).The levels of ALT,TC,LDL-C and TG in treatment group after treatment were(47.28±10.41)U/L,(4.28±0.29)mmol/l,(2.25±0.42)mmol/l and(1.96±0.33)mmol/l,which was significantly lower than that of control group,but the levels of HDL-C was(1.69±0.32)mmol/l,which was significantly higher than that of control group(P0.05);No obvious adverse reactions happened in two groups during treatment.Conclusion The treatment of rosiglitazone combined with bicyclol has a good effect on non-alcoholic fatty liver without adverse reaction.It could significantly improve liver function,blood lipids and imaging.
Publication Year: 2012
Publication Date: 2012-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot